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Abstract
Purpose Long-term usage of the antiarrhythmic drug
digoxin has been connected to lowered risk of prostate
cancer. A recent study has suggested that beta-blockers
might also have similar risk-decreasing effects. We eval-
uated the association between use of digoxin, beta-blocker
sotalol, and other antiarrhythmic drugs and prostate cancer
risk in a retrospective cohort study.
Methods Our study population consisted of men in the
Finnish Prostate Cancer Screening Trial during 1996–2012
(n = 78,615). During median follow-up of 12 years, 6,639
prostate cancer cases were diagnosed. The national pre-
scription database was the source of the information of
antiarrhythmic drug purchases. Data were analyzed using
Cox regression method with medication use as a time-de-
pendent variable.
Results No association was found for overall prostate
cancer risk with antiarrhythmic drug use (HR 1.05 95% CI
0.94–1.18). Neither sotalol (HR 0.97 95% CI 0.76–1.24) nor
digoxin (HR 1.01 95% CI 0.87–1.16) users had a decreased
risk of prostate cancer. Similar results were obtained for
high-grade (Gleason 7–10) and metastatic prostate cancer.
Nevertheless, the risk estimates for Gleason 7–10 prostate
cancer tended to decrease by duration of digoxin use (p for
trend = 0.052), suggesting that the drug may reduce the risk
in long-term usage (HR 0.71, 95% CI 0.49–1.03). In analysis
stratified by screening trial arm, the protective association
against Gleason 7–10 disease was observed only in the
screening arm (HR 0.31, 95% CI 0.12–0.84 for men who had
used digoxin for 5 years or longer).
Conclusion Digoxin or other antiarrhythmic drugs are not
associated with any clear decrease in prostate cancer risk.
However, digoxin might have a benefit in long-term use by
reducing risk of high-grade disease. Further research will
be needed to evaluate possible effects on prostate cancer
survival.
Keywords Prostate cancer  Risk  Digoxin  Cohort 
Antiarrhythmic drugs
Introduction
Despite being the most common cancer among men,
prostate cancer etiology remains poorly understood. Even
minor preventive effects would have major benefits to both
public health and economics. The American Cancer Soci-
ety estimates that in 2011, 240,890 men were diagnosed
with prostate cancer and 33,720 men died because of the
disease in the USA [1]. As little as one percent reduction in
population risk of prostate cancer would mean that thou-
sands of cancers did not occur [2].
The antiarrhythmic drug digoxin has been suggested to
have prostate cancer preventive effects both by in vitro and
by epidemiological studies [3, 4]. In vitro digoxin inhibits
plasma membrane Na?/K?-ATPase and disarrays intra-
cellular K? and Ca2? concentrations [4]. An increased
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Ca2? concentration in the cell increases apoptosis [5]. In
support of digoxin’s beneficial effects, a large cohort study
(47,884 men) recently showed decreased prostate cancer
incidence among men who had used digoxin constantly for
over 10 years [4] and a case–control (1,001 cases and 942
controls) study reported the prostate cancer risk was
decreased in digoxin users, especially among men with 3 or
more PSA tests during the past 5 years [3].
Beta-blockers are usually used for management of
hypertension but sotalol, which is both a beta- and a K?-
channel blocker, is a common antiarrhythmic drug. It has
been suggested that regular use of beta-blockers is asso-
ciated with decreased risk of cancer [6]. We have previ-
ously shown that sotalol users may have lowered prostate
cancer risk [7].
We analyzed how use of digoxin, sotalol, or other
antiarrhythmic drugs is linked with overall prostate cancer
risk and with tumor characteristics at diagnosis in a cohort
of men participating in the Finnish Prostate Cancer
Screening Trial.
Materials and methods
Study population
The study cohort consisted of men randomized to the
Finnish Prostate Cancer Screening Trial (FinRSPC) during
1996–1999 and followed up until the end of 2012. The
FinRSPC protocol has been previously described in detail
[8]. In brief, 80,456 men aged 55–67 years and living in the
metropolitan areas of Tampere and Helsinki, Finland, were
identified from the Population Register Center and ran-
domized either to be screened for prostate cancer with PSA
test at 4-year intervals (31,866 men, the screening arm) or
to be followed through the national Finnish Cancer Reg-
istry (48,278 men, the control arm).
Information on prostate cancers cases diagnosed in the
study population included information on tumor Gleason
grade at diagnosis, TNM stage, serum PSA value (for the
screening arm), and the date and method of diagnosis.
Prostate cancer was diagnosed in 6,639 men of the study
population before 2010. The method of detection was
known for 6,082 cases (91.6 %). Of these, 2,584 (42.5 %)
were detected through screening, 1,938 (31.9 %) between
the screening rounds, 327 (5.4 %) in men invited to
screening but not participating and 29 (0.5 %) in autopsy.
Most cases were histologically confirmed (98.1 %). Other
methods of diagnostic verification included clinical (0.3 %)
and at autopsy (1.6 %). One case was only radiologically
and one cytologically confirmed. The method of diagnosis
was unknown in three cases.
The study was approved by the ethics committee of the
Pirkanmaa health care district, Finland (tracking number
ETL 95077).
Information on medication use
Data of refunded physician-prescribed medication pur-
chases for the entire cohort during 1995–2009 were col-
lected from the nationwide prescription database of the
Social Insurance Institution (SII) of Finland. SII provides
reimbursements for the costs of medicine prescribed by a
physician for all Finnish residents [9]. Every reimbursed
purchase of a prescribed drug is registered in the database.
The information in the registry includes date for each
purchase, number of packages obtained, as well as the
number and dosage of pills.
Information on drugs categorized as antiarrhythmic in
Pharmaca Fennica, the Finnish national pharmaceutical
guide, was collected: amiodarone, digoxin, disopyramide,
etilefrine, flecainide, quinidine, mexiletine, procainamide,
propafenone, and sotalol. All drugs were available for
every year of the study follow-up except etilefrine
(1995–2008) and procainamide (only 1995). The purchases
of most drugs reduced significantly over time. For exam-
ple, 6,110 men bought digoxin in 1997 but only 1,815 in
2009. Only purchases of flecainide increased from 92 (in
1995) to 473 (in 2009) during the study. Purchases of
amiodarone and propafenone remained constant. Informa-
tion on medication use was available for 78,615 men
(98.1 % of the entire screening trial population).
Statistical analysis
We used Cox regression method to analyze prostate cancer
risk overall, as well as by stage and Gleason grade. We
performed age-adjusted and multivariable analyses (further
adjustment for use of other drug groups: NSAIDs, aspirin,
antidiabetic medication, statins, antihypertensives, 5alpha-
reductase inhibitors, and alpha-blockers). Multivariable-
adjusted risk estimates are reported unless otherwise stated.
We analyzed class effect of antiarrhythmic drugs by
comparing users of any antiarrhythmic drugs to non-users.
Drug-specific effects were separately analyzed for digoxin
and sotalol. Men who had used both drug groups were
included in both analyses. Sensitivity analyses with further
adjustment for digoxin or sotalol usage were performed to
adjust for simultaneous usage.
Medication use status was updated prospectively each
year of follow-up based on yearly medication purchases.
Men with recorded purchases at any given year were
regarded as users for that year. Users with a full year
without purchases changed status into previous users. The
status was allowed to change back to users if drug
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purchases were resumed at later point of follow-up. Never
users and all users before the first purchase were classified
as non-users. Non-users were used as the reference group
in all analyses.
The amount of antiarrhythmic drug use was standard-
ized by dividing the yearly mg amount of each drug with
the standard defined daily dose (DDD) published in public
WHO website [10]. Duration of usage was calculated as
number of years with medication purchases. Intensity of
use (DDDs/year) was calculated by dividing the yearly
cumulative amount with the number of years of usage. In
men who stopped previous usage before the end of follow-
up, the cumulative amount, duration, and intensity of use
remained at the level reached before discontinuation.
Cumulative amount (DDDs), duration (years), and
intensity (DDDs/year) of medication use were also updated
prospectively according to the yearly purchases. Men dis-
continuing previous use retained the level reached before
the discontinuation. Trends in prostate cancer risk by
amount, duration, and intensity of the medication use were
evaluated by stratifying the cohort by tertiles and repeating
the analysis for each stratum. Additionally, we analyzed
the trends by adding the cumulative amount/duration/in-
tensity of use as a continuous variable into the Cox
regression model. These analyses were necessary to esti-
mate the association between prostate cancer risk and long-
term drug usage, which was linked with reduced risk in the
previous study [3].
Subgroup analyses were performed by stratifying the
population by baseline characteristics, screening trial arm,
and usage of other drug groups. We estimated effect
modification by these variables on prostate cancer risk
among antiarrhythmic medication users by adding inter-
action term with medication use into the Cox regression
model. Furthermore, we estimated the effect of confound-
ing by indication comparing digoxin users to men using
other types of antiarrhythmic drugs or antihypertensive
drugs.
We used v2-test to estimate the statistical significance of
differences in population characteristics by antiarrhythmic
drug use.
All statistical tests are two-sided; p values 0.05 or less
were considered statistically significant. IBM SPSS
Statistics 22 (Chicago, IL, USA) software was used for data
analyses.
Results
Population characteristics
The overall prevalence of antiarrhythmic drug use was
10.3 % (8,064 men). The prevalence of digoxin use was
7.2 % (5,668 men) and for sotalol 3.2 % (2,540 men).
Median age at baseline among never users of antiarrhyth-
mic drugs was 59 years. Among users the median age was
slightly greater, 63 years. A similar difference was
observed between ever and never users of digoxin and
sotalol. No differences were observed in baseline PSA
levels by antiarrhythmic drug use (Table 1).
During the median follow-up of 12 years, 6,639 prostate
cancer cases were diagnosed within the cohort. Compared
to non-users of antiarrhythmic drugs, the users had lower
cumulative incidence of high-grade (Gleason 7–10) tumors
(42.2 vs. 39.2 %) and metastatic disease at diagnosis (6.29
vs. 5.89 %, respectively) (Table 1). The incidence of high-
grade disease was also slightly lower among users of
digoxin (40.8 vs. 39.2 % in non-users and users, respec-
tively) and sotalol (41.9 vs. 40.2 %).
The usage of other drug groups (NSAIDs, aspirin, 5alfa-
reductase inhibitors, alpha-blockers, antihypertensive
drugs, antidiabetic drugs, and statins) was more frequent
among antiarrhythmic drug users compared to the non-
users (Table 1).
Antiarrhythmic drugs in general and prostate
cancer
Overall prostate cancer risk was slightly elevated among
current antiarrhythmic drug users compared to non-users in
the age-adjusted analysis, but not in the multivariable-ad-
justed analysis (Table 2). No significant association was
observed for risk of either high-grade or metastatic prostate
cancer.
The overall prostate cancer risk increased slightly by
cumulative amount and intensity of antiarrhythmic drug
use, although the trend was not significant (Table 3). This
trend, however, was not observed for high-grade cancer.
For metastatic cancer, the risk was elevated at the begin-
ning of usage, i.e., men whose cumulative amount was
lowest, but not with continued use.
Digoxin use and prostate cancer
Overall, digoxin use was not associated with prostate
cancer risk or with tumor grade or stage (Table 2). How-
ever, the association between digoxin use and prostate
cancer was modified by prostate cancer screening; digoxin
users had a borderline significantly decreased prostate
cancer risk in the screening arm (HR 0.82, 95% CI
0.64–1.04) but not in the control arm (p for interac-
tion = 0.052) (Table 2).
Risk estimates for high-grade and metastatic prostate
cancer tended to decrease with increasing amount and
duration of digoxin use (Table 3), but remained statistically
non-significant. A borderline significant decrease in the
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risk of high-grade prostate cancer was observed among
men who used digoxin for 6 years or longer (HR 0.71, 95%
CI 0.49–1.03). A similar decrease in the risk estimate was
also observed for metastatic disease in long-term users (HR
0.80, 95% CI 0.30–2.16). No clear trends in risk estimates
were observed for intensity of digoxin use.
Among men in the screening arm, a significant risk
reduction for Gleason 7–10 prostate cancer was observed
for men who have used digoxin for longer than 5 years
(HR 0.31, 95% CI 0.12–0.84). Antiarrhythmic drug use in
general among the same sub-cohort (screening arm, longer
than 5 years of drug usage) was not associated with sig-
nificant risk reduction (HR 0.64, 95% CI 0.40–1.02).
Sotalol use and prostate cancer
No risk association was observed with sotalol use for
overall, high-grade, and metastasized prostate cancer risks
(Table 2).
The amount of sotalol usage was not associated with
overall or high-grade prostate cancer risk. No significant
risk difference was observed for metastatic disease, either
(Table 3).
Subgroup analyses
Age at randomization modified the association between
antiarrhythmic drugs and prostate cancer risk; the risk was
lower in men aged 55–59 years at baseline (p for interac-
tion = 0.001). The overall prostate cancer risk was
decreased among 55- to 59-year-old current sotalol user
compared to non-users; HR 0.54, 95% CI 0.30–0.97. This
difference was not seen in the older age group (p for
interaction = 0.006) (Table 4).
Prostate cancer risk in digoxin users did not differ from
men using other types of antiarrhythmic drugs in a sensi-
tivity analysis limited to drug users only (HR 0.96, 95% CI
0.81–1.15). No risk difference was observed for high-grade
or metastatic disease, either. Further, digoxin use was not
associated with prostate cancer risk in analysis with anti-
hypertensive drug users as the comparison group (HR 1.00,
95% CI 0.86–1.16).
Use of other medications did not modify the effect of
antiarrhythmic drugs (Table 4). The sensitivity analyses to
estimate the effect of simultaneous usage of digoxin and
sotalol did not show any differences in prostate cancer risk
estimates.
Table 1 Population characteristics
Use of antiarrhythmic drugs Use of digoxin Use of sotalol
Never Ever p value Never Ever p value Never Ever p value
No. of cases 5,807 730 6,052 485 6,296 241
Gleason 6 or less
tumor
3,203
(55.1 %)
419
(57.4 %)
3,343
(55.3 %)
279
(57.5 %)
3,488
(55.4 %)
134
(55.6 %)
Gleason 7–10 2,450
(42.2 %)
286
(39.2 %)
2,456
(40.8 %)
190
(39.2 %)
2,639
(41.9 %)
97 (40.2 %)
Metastatic cases 365 (6.29 %) 43 (5.89 %) 376 (6.21 %) 32 (6.60 %) 392 (6.23 %) 16 (6.64 %)
Median PSA-level (ng/
ml)
1.07 1.07 0.49 1.07 1.08 0.59 1.08 1.01 0.28
Use of other drugs
NSAIDs 55,664
(78.9 %)
6,609
(82.0 %)
0.001 57,722
(79.1 %)
4,551
(80.3 %)
0.039 60,131
(79.0 %)
2,142
(84.3 %)
0.001
Aspirin 10,894
(15.4 %)
1,485
(18.4 %)
0.001 11,409
(15.6 %)
970
(17.1 %)
0.004 11,832
(15.6 %)
547
(21.5 %)
0.001
Statins 28,526
(40.4 %)
4,238
(53.7 %)
0.001 29,905
(41.0 %)
2,949
(52.0 %)
0.001 31,339
(41.2 %)
1,515
(59.6 %)
0.001
Antidiabetic drugs 13,453
(19.1 %)
2,440
(30.3 %)
0.001 13,979
(19.2 %)
1,914
(33.8 %)
0.001 15,177
(20.0 %)
716
(28.2 %)
0.001
Antihypertensives 45,183
(64.0 %)
7,748
(96.1 %)
0.001 47,372
(64.9 %)
5,559
(98.1 %)
0.001 50,489
(66.4 %)
2,442
(96.1 %)
0.001
5alpha-reductase
inhibitors
8,538
(12.1 %)
1,148
(14.2 %)
0.001 8,946
(12.3 %)
740
(13.1 %)
0.081 9,299
(12.2 %)
387
(15.2 %)
0.001
Alpha-blockers 18,776
(26.6 %)
2,567
(31.8 %)
0.001 19,643
(26.9 %)
1,700
(30.0 %)
0.001 20,491
(26.9 %)
852
(33.5 %)
0.001
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Discussion
We did not find a clear association between antiarrhythmic
drug usage and prostate cancer risk. Similarly, neither
usage of digoxin nor sotalol had an influence on the risk.
Nonetheless, the risk estimates for high-grade and meta-
static prostate cancer tended to decrease by increasing
cumulative amount and duration of digoxin use. However,
a similar decreasing trend was observed also for antiar-
rhythmic drugs in general and could thus be due to
systematic differences between users and non-users of this
drug group rather than due to digoxin usage. However, the
risk reduction for Gleason 7–10 cancer in the screening
arm was observed only for long-term users of digoxin.
Thus, our results lend some support for oncological bene-
fits of long-term digoxin use, as previously reported by
Platz et al. [3] in a case–control study.
We must consider the possibility that the observed risk
associations result from confounding by indication. When
digoxin users were compared to other antiarrhythmic drug
Table 2 Prostate cancer risk, overall, and by grade and stage in antiarrhythmic drug users
Overall risk n All FinPCST participants Screening arm Control arm
Age-adjusted
analysis
Multivariable-adjusted
analysisa
Multivariable-adjusted
analysisa,b
Multivariable-adjusted
analysisa,b
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
All antiarrhythmic drugs
Users 319 1.13 (1.01–1.27) 1.05 (0.94–1.18) 0.97 (0.81–1.16) 1.09 (0.94–1.26)
Previous users 197 1.08 (0.93–1.26) 1.00 (0.86–1.17) 1.00 (0.78–1.28) 0.99 (0.81–1.21)
Digoxin
Users 191 1.06 (0.92–1.23) 1.01 (0.87–1.16) 0.82 (0.64–1.04) 1.13 (0.94–1.35)
Previous users 135 1.09 (0.90–1.31) 1.03 (0.85–1.24) 1.08 (0.81–1.43) 0.97 (0.76–1.25)
Sotalol
Users 63 1.05 (0.82–1.34) 0.97 (0.76–1.24) 0.88 (0.60–1.30) 1.05 (0.76–1.45)
Previous users 129 1.16 (0.96–1.41) 1.07 (0.88–1.29) 1.13 (0.84–1.54) 1.02 (0.80–1.30)
Gleason 7–10 prostate cancer risk
All antiarrhythmic drugs
Users 118 0.99 (0.82–1.19) 0.90 (0.74–1.08) 0.92 (0.67–1.25) 0.88 (0.70–1.11)
Previous users 100 1.17 (0.95–1.44) 1.06 (0.86–1.31) 1.23 (0.87–1.74) 0.97 (0.74–1.26)
Digoxin
Users 73 0.94 (0.75–1.19) 0.87 (0.69–1.10) 0.67 (0.43–1.04) 0.97 (0.73–1.27)
Previous users 66 1.12 (0.86–1.46) 1.04 (0.80–1.35) 1.28 (0.85–1.93) 0.91 (0.64–1.29)
Sotalol
Users 25 1.11 (0.75–1.65) 1.03 (0.69–1.52) 1.25 (0.69–2.26) 0.91 (0.54–1.54)
Previous users 57 1.10 (0.83–1.46) 1.00 (0.75–1.33) 1.40 (0.90–2.16) 0.81 (0.56–1.18)
Metastatic prostate cancer riskc
All antiarrhythmic drugs
Users 24 1.33 (0.88–2.01) 1.21 (0.80–1.83) 1.48 (0.71–3.07) 1.10 (0.66–1.84)
Previous users 12 1.03 (0.55–1.93) 0.94 (0.50–1.77) 0.74 (0.18–3.02) 1.00 (0.49–2.03)
Digoxin
Users 15 1.29 (0.77–2.16) 1.14 (0.68–1.92) 1.06 (0.39–2.90) 1.18 (0.64–2.16)
Previous users 11 1.39 (0.72–2.70) 1.25 (0.64–2.44) 1.02 (0.25–4.18) 1.34 (0.63–2.85)
Sotalol
Users 6 1.55 (0.69–3.46) 1.49 (0.67–3.35) 1.83 (0.45–7.43) 1.36 (0.50–3.65)
Previous users 5 0.87 (0.36–2.11) 0.83 (0.34–2.01) 2.23 (0.70–7.10) 0.42 (0.10–1.68)
a From Cox regression model adjusted for age, screening trial arm and use of cholesterol-lowering, antidiabetic and antihypertensive drugs,
aspirin and other NSAIDs, and 5alpha-reductase inhibitors and alpha-blockers
b p for interaction in risk of prostate cancer among digoxin users by FinPCST study arm = 0.052
c Stage M1 at diagnosis
Cancer Causes Control (2016) 27:157–164 161
123
T
a
b
le
3
P
ro
st
at
e
ca
n
ce
r
ri
sk
b
y
cu
m
u
la
ti
v
e
am
o
u
n
t,
d
u
ra
ti
o
n
,
an
d
in
te
n
si
ty
o
f
an
ti
ar
rh
y
th
m
ic
d
ru
g
u
sa
g
e
H
R
(9
5
%
C
I)
m
u
lt
iv
a
ri
a
b
le
-a
d
ju
st
e
d
a
A
ll
an
ti
ar
rh
y
th
m
ic
d
ru
g
s
D
ig
o
x
in
S
o
ta
lo
l
O
v
er
al
l
P
C
a
ri
sk
H
ig
h
-g
ra
d
e
P
C
a
ri
sk
R
is
k
o
f
m
et
as
ta
ti
c
d
is
ea
se
O
v
er
al
l
P
C
a
ri
sk
H
ig
h
-g
ra
d
e
P
C
a
ri
sk
R
is
k
o
f
m
et
as
ta
ti
c
d
is
ea
se
O
v
er
al
l
P
C
a
ri
sk
H
ig
h
-g
ra
d
e
P
C
a
ri
sk
R
is
k
o
f
m
et
as
ta
ti
c
d
is
ea
se
A
m
o
u
n
t
o
f
m
ed
ic
at
io
n
u
se
b
1
st
T
er
ti
le
0
.9
7
(0
.8
3
–
1
.1
3
)
1
.0
1
(0
.8
0
–
1
.2
7
)
1
.6
3
(1
.0
1
–
2
.6
3
)
1
.0
1
(0
.8
4
–
1
.2
3
)
0
.9
0
(0
.6
6
–
1
.2
2
)
1
.2
7
(0
.6
5
–
2
.4
6
)
0
.9
1
(0
.7
0
–
1
.1
9
)
0
.8
4
(0
.5
5
–
1
.2
7
)
1
.3
5
(0
.5
6
–
3
.2
7
)
2
n
d
T
er
ti
le
1
.0
3
(0
.8
8
–
1
.2
0
)
0
.9
6
(0
.7
6
–
1
.2
3
)
0
.9
4
(0
.5
0
–
1
.7
6
)
0
.9
9
(0
.8
1
–
1
.2
1
)
1
.1
2
(0
.8
5
–
1
.4
9
)
1
.2
9
(0
.6
6
–
2
.5
0
)
1
.0
3
(0
.8
0
–
1
.3
2
)
1
.0
8
(0
.7
4
–
1
.5
8
)
0
.8
0
(0
.2
6
–
2
.5
0
)
3
rd
T
er
ti
le
1
.1
2
(0
.9
6
–
1
.3
1
)
0
.9
1
(0
.7
1
–
1
.1
6
)
0
.6
8
(0
.3
0
–
1
.5
2
)
1
.0
5
(0
.8
6
–
1
.2
8
)
0
.7
9
(0
.5
7
–
1
.1
0
)
0
.9
6
(0
.4
3
–
2
.1
7
)
1
.1
8
(0
.9
0
–
1
.5
5
)
1
.1
4
(0
.7
6
–
1
.6
8
)
1
.1
5
(0
.3
7
–
3
.6
0
)
p
fo
r
tr
en
d
0
.2
4
0
.4
6
0
.7
4
0
.7
6
0
.3
9
0
.6
2
0
.3
9
0
.6
3
0
.8
8
D
u
ra
ti
o
n
o
f
m
ed
ic
at
io
n
u
se
c
1
st
T
er
ti
le
1
.0
1
(0
.8
8
–
1
.1
6
)
1
.0
6
(0
.8
6
–
1
.3
2
)
1
.4
1
(0
.8
9
–
2
.2
5
)
1
.0
4
(0
.8
8
–
1
.2
2
)
1
.0
3
(0
.8
0
–
1
.3
2
)
1
.4
4
(0
.8
4
–
2
.4
6
)
0
.9
1
(0
.7
0
–
1
.1
9
)
0
.7
8
(0
.5
0
–
1
.2
1
)
1
.3
1
(0
.5
4
–
3
.1
7
)
2
n
d
T
er
ti
le
1
.1
2
(0
.9
7
–
1
.2
9
)
0
.9
4
(0
.7
4
–
1
.2
0
)
1
.1
3
(0
.6
3
–
2
.0
3
)
1
.0
1
(0
.8
2
–
1
.2
5
)
1
.0
1
(0
.7
4
–
1
.3
9
)
1
.0
7
(0
.4
7
–
2
.4
0
)
1
.1
4
(0
.8
9
–
1
.4
5
)
1
.2
9
(0
.9
1
–
1
.8
3
)
1
.3
8
(0
.5
7
–
3
.3
5
)
3
rd
T
er
ti
le
0
.9
4
(0
.7
7
–
1
.1
5
)
0
.8
3
(0
.6
2
–
1
.1
1
)
0
.4
5
(0
.1
4
–
1
.4
2
)
0
.9
7
(0
.7
7
–
1
.2
3
)
0
.7
1
(0
.4
9
–
1
.0
3
)
0
.8
0
(0
.3
0
–
2
.1
6
)
1
.0
5
(0
.7
9
–
1
.4
0
)
0
.9
7
(0
.6
3
–
1
.4
7
)
0
.3
8
(0
.0
5
–
2
.7
2
)
p
fo
r
tr
en
d
0
.6
1
0
.2
8
0
.7
8
0
.9
8
0
.2
0
0
.8
5
0
.5
2
0
.7
3
0
.8
8
In
te
n
si
ty
o
f
m
ed
ic
at
io
n
u
se
d
1
st
T
er
ti
le
1
.0
3
(0
.8
7
–
1
.2
1
)
1
.0
7
(0
.8
5
–
1
.3
5
)
1
.5
7
(0
.9
3
–
2
.6
5
)
0
.9
3
(0
.8
1
–
1
.2
0
)
0
.9
2
(0
.6
8
–
1
.2
4
)
1
.3
4
(0
.6
9
–
2
.6
0
)
1
.0
5
(0
.8
1
–
1
.3
7
)
0
.9
9
(0
.6
6
–
1
.4
8
)
1
.2
0
(0
.4
5
–
3
.2
2
)
2
n
d
T
er
ti
le
0
.8
5
(0
.7
1
–
1
.0
2
)
0
.6
8
(0
.5
1
–
0
.9
1
)
0
.8
5
(0
.4
2
–
1
.7
1
)
0
.7
9
(0
.6
1
–
1
.0
1
)
0
.6
7
(0
.4
6
–
0
.9
9
)
0
.9
2
(0
.3
8
–
2
.2
2
)
0
.8
5
(0
.6
4
–
1
.1
4
)
0
.7
1
(0
.4
4
–
1
.1
5
)
0
.6
1
(0
.1
5
–
2
.4
5
)
3
rd
te
rt
il
e
1
.1
9
(1
.0
3
–
1
.3
6
)
1
.1
0
(0
.8
9
–
1
.3
6
)
0
.9
5
(0
.5
2
–
1
.7
4
)
1
.1
9
(1
.0
1
–
1
.4
1
)
1
.1
5
(0
.8
9
–
1
.4
9
)
1
.2
3
(0
.6
5
–
2
.3
1
)
1
.1
8
(0
.9
3
–
1
.5
0
)
1
.3
1
(0
.9
3
–
1
.8
5
)
1
.4
5
(0
.6
0
–
3
.5
2
)
p
fo
r
tr
en
d
0
.2
1
0
.6
9
0
.9
9
0
.3
9
0
.8
5
0
.5
2
0
.5
5
0
.6
0
0
.6
9
a
F
ro
m
C
o
x
re
g
re
ss
io
n
m
o
d
el
ad
ju
st
ed
fo
r
ag
e,
sc
re
en
in
g
tr
ia
l
ar
m
an
d
u
se
o
f
ch
o
le
st
er
o
l-
lo
w
er
in
g
,
an
ti
d
ia
b
et
ic
an
d
an
ti
h
y
p
er
te
n
si
v
e
d
ru
g
s,
as
p
ir
in
an
d
o
th
er
N
S
A
ID
s,
an
d
5
al
p
h
a-
re
d
u
ct
as
e
in
h
ib
it
o
rs
an
d
al
p
h
a-
b
lo
ck
er
s
b
T
er
ti
le
cu
t-
p
o
in
ts
fo
r
cu
m
u
la
ti
v
e
am
o
u
n
t
o
f
m
ed
ic
at
io
n
u
se
:
A
ll
an
ti
ar
rh
y
th
m
ic
d
ru
g
s
co
m
b
in
ed
1
st
te
rt
il
e:
1
–
3
0
0
D
D
D
,
2
n
d
te
rt
il
e:
3
0
1
–
1
,3
5
0
D
D
D
,
3
rd
te
rt
il
e:
m
o
re
th
an
1
,3
5
0
D
D
D
;
d
ig
o
x
in
1
st
te
rt
il
e:
1
–
2
0
0
D
D
D
,
2
n
d
te
rt
il
e:
2
0
1
–
9
0
0
D
D
D
,
3
rd
te
rt
il
e:
m
o
re
th
an
9
0
0
D
D
D
;
so
ta
lo
l
1
st
te
rt
il
e:
1
–
2
0
0
D
D
D
,
2
n
d
te
rt
il
e:
2
0
1
–
1
,2
0
0
D
D
D
,
3
rd
te
rt
il
e:
m
o
re
th
an
1
,2
0
0
D
D
D
c
T
er
ti
le
cu
t-
p
o
in
ts
fo
r
cu
m
u
la
ti
v
e
d
u
ra
ti
o
n
o
f
m
ed
ic
at
io
n
u
se
:
A
ll
an
ti
ar
rh
y
th
m
ic
d
ru
g
s
co
m
b
in
ed
1
st
te
rt
il
e:
1
–
2
y
ea
rs
,
2
n
d
te
rt
il
e:
3
–
6
y
ea
rs
,
3
rd
te
rt
il
e:
lo
n
g
er
th
an
6
y
ea
rs
;
d
ig
o
x
in
1
st
te
rt
il
e:
1
–
2
y
ea
rs
,
2
n
d
te
rt
il
e:
3
–
5
y
ea
rs
,
3
rd
te
rt
il
e:
lo
n
g
er
th
an
5
y
ea
rs
;
so
ta
lo
l
1
st
te
rt
il
e:
1
y
ea
r,
2
n
d
te
rt
il
e:
2
–
4
y
ea
rs
,
3
rd
te
rt
il
e:
lo
n
g
er
th
an
4
y
ea
rs
d
T
er
ti
le
cu
t-
p
o
in
ts
fo
r
in
te
n
si
ty
o
f
m
ed
ic
at
io
n
u
se
:
A
ll
an
ti
ar
rh
y
th
m
ic
d
ru
g
s
co
m
b
in
ed
1
st
te
rt
il
e:
1
–
1
2
5
D
D
D
s/
y
ea
r,
2
n
d
te
rt
il
e:
1
2
6
–
2
5
0
D
D
D
s/
y
ea
r,
3
rd
te
rt
il
e:
m
o
re
th
an
2
5
0
D
D
D
s/
y
ea
r;
d
ig
o
x
in
1
st
te
rt
il
e:
1
–
1
0
0
D
D
D
s/
y
ea
r,
2
n
d
te
rt
il
e:
1
0
1
–
1
8
5
D
D
D
s/
y
ea
r,
3
rd
te
rt
il
e:
m
o
re
th
an
1
8
5
D
D
D
s/
y
ea
r;
so
ta
lo
l
1
st
te
rt
il
e:
1
–
1
1
5
D
D
D
s/
y
ea
r,
2
n
d
te
rt
il
e:
1
1
6
–
2
8
0
D
D
D
s/
y
ea
r,
3
rd
te
rt
il
e:
m
o
re
th
an
2
8
0
D
D
D
s/
y
ea
r
162 Cancer Causes Control (2016) 27:157–164
123
users, i.e., within the group supposedly having similar
indications for drug usage, no protective risk differences
were observed.
Besides being used in treatment of atrial fibrillation,
digoxin is also used in management of congestive heart
failure. Antihypertensive drugs are also commonly used in
heart failure patients. However, no risk association was
found when digoxin users were compared to these anti-
hypertensive drug users.
The Health Professionals Follow-up study demonstrated
that long-term digoxin users ([10 years) had a lowered
prostate cancer risk (RR 0.54 95% CI 0.37–0.79, p-
trend\ 0.001) [4]. Our study cohort was larger (78,615 vs.
47,884) with more prostate cancer diagnoses (6,639 vs.
Table 4 Prostate cancer risk by
antiarrhythmic drug usage in
subgroups stratified by baseline
variables
HR (95% CI)multivariable-adjusted
a
All Antiarrhythmic drugs Digoxin Sotalol
Age at randomization
55–59 0.84 (0.68–1.04) 0.90 (0.68–1.18) 0.54 (0.30–0.97)
63–67 1.09 (0.95–1.25) 0.99 (0.84–1.18) 1.08 (0.82–1.41)
p for interaction 0.001 0.143 0.006
Antiarrhythmic drug use before randomization
No 0.96 (0.81–1.13) 0.93 (0.75–1.15) 0.99 (0.70–1.40)
Yes 1.11 (0.79–1.55) 0.96 (0.73–1.25) 0.87 (0.59–1.28)
p for interaction 0.42 0.72 0.65
NSAID usage
Non-users 1.26 (0.95–1.68) 1.19 (0.84–1.69) 1.40 (0.75–2.62)
Users 1.02 (0.90–1.15) 0.97 (0.83–1.14) 0.92 (0.70–1.21)
p for interaction 0.843 0.474 0.401
ASA usage
Non-users 1.08 (0.96–1.22) 1.04 (0.89–1.21) 0.92 (0.69–1.22)
Users 0.91 (0.66–1.24) 0.83 (0.54–1.27) 1.26 (0.74–2.13)
p for interaction 0.820 0.468 0.222
Antidiabetic drug usage
Non-users 1.06 (0.93–1.22) 1.00 (0.83–1.20) 1.00 (0.75–1.32)
Users 1.02 (0.82–1.25) 1.02 (0.80–1.30) 0.89 (0.54–1.48)
p for interaction 0.155 0.446 0.434
Statin usage
Non-users 1.13 (0.95–1.33) 1.11 (0.90–1.36) 0.95 (0.67–1.43)
Users 1.00 (0.86–1.17) 0.93 (0.76–1.14) 0.98 (0.71–1.34)
p for interaction 0.687 0.555 0.880
Antihypertensive drug usage
Non-users 1.13 (0.61–2.11) 1.34 (0.50–3.58) 0.51 (0.13–2.03)
Users 1.05 (0.94–1.18) 1.00 (0.86–1.16) 1.00 (0.78–1.29)
p for interaction 0.222 0.883 0.528
5alpha-reductase inhibitor usage
Non-users 1.04 (0.92–1.18) 1.00 (0.85–1.17) 0.96 (0.74–1.26)
Users 1.07 (0.80–1.43) 1.05 (0.71–1.54) 0.97 (0.50–1.87)
p for interaction 0.958 0.878 0.584
Alpha-blocker usage
Non-users 1.05 (0.90–1.24) 0.95 (0.77–1.17) 1.04 (0.74–1.45)
Users 1.03 (0.88–1.20) 1.04 (0.85–1.27) 0.91 (0.63–1.31)
p for interaction 0.750 0.765 0.275
a From Cox regression model adjusted for age, screening trial arm and use of cholesterol-lowering,
antidiabetic and antihypertensive drugs, aspirin and other NSAIDs, and 5alpha-reductase inhibitors and
alpha-blockers
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5,002) and more digoxin users (485 vs. 243). In the pre-
vious study, only 28 men had used digoxin over 10 years.
We categorized the use of 6 years or more as long-term
usage. Our study population consisted of 305 long-term
users and 175 men who have used digoxin for over
10 years. Therefore, our study had greater statistical power
to study the long-term effects of these drugs. It should be
noted that we observed a protective risk association for
long-term digoxin use only among men under prostate
cancer screening, not in the control arm. Due to widespread
PSA testing in the USA, participants of the Health Pro-
fessionals Follow-up study were likely in regular PSA
surveillance. Thus, our results are in concordance with this
previous study.
Our study cohort also has some similarities to the Health
Professionals study. At the beginning of the follow-up,
participants were 40–75 years old in the US study, whereas
the age of our study population was 55–67 at the start of the
follow-up. Both cohorts consisted mostly of Caucasians, so
ethnicity is unlikely to be a confounding factor.
Our study has some strengths. Our information on
medication use was comprehensive with minimal mis-
classification; a possible recall bias is excluded in our study
as medication purchases are recorded by the database
regardless of cancer status. Another important strength of
our study is the large study population consisting of men
living in two metropolitan areas in Finland. The study
cohort was large enough to analyze the influence of an
uncommonly used drug, such as digoxin, on the risk of
prostate cancer, even by disease grade and stage. In com-
parison with the previous US study, our information on
medication use was not collected from surveys but from
objectively recorded national registry data.
Some limitations should be considered. First, from the
nationwide prescription database of the SII of Finland we
were able to obtain the purchase information of any
reimbursed drugs. Conversely, the exact indication for the
purchases of the antiarrhythmic drugs was not available
and thus we were not able to control for indication of drug
usage in our analysis. However, evidence linking cardiac
arrhythmias to prostate cancer risk is sparse. We were able
control for underlying diseases indirectly by adjusting for
the usage of other drug groups.
Second, we had no information on lifestyle factors.
Previous studies have showed that factors such as exercise,
BMI, smoking, and diet might have an impact on the risk of
prostate cancer [11]. These could have caused confounding
in either direction depending on their distribution between
the users and non-users of the antiarrhythmic drugs.
Third, we did not have information about whether the
received drugs were actually used. This might have caused
exposure misclassification and bias toward the null.
Conclusion
In conclusion, neither antiarrhythmic drug usage in gen-
eral, nor digoxin or sotalol usage impacted the overall risk
of prostate cancer. Nonetheless, our study does lend some
support for the protective effect of long-term usage of
digoxin, as the risk estimates for high-grade (Gleason score
7–10) cancer tended to decrease as the cumulative years of
digoxin use increase. This effect was more distinct among
men in the screening arm. Further studies should address
whether or not digoxin use affects prostate cancer
mortality.
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